| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0022-3476(05)81609-9 |
| P698 | PubMed publication ID | 2181099 |
| P2093 | author name string | Morrison BJ | |
| Anderson JD | |||
| Carter JE | |||
| Cimolai N | |||
| P2860 | cites work | Risk factors for development of hemolytic uremic syndrome during shigellosis | Q33449679 |
| A severe outbreak of Escherichia coli O157:H7--associated hemorrhagic colitis in a nursing home | Q33450098 | ||
| Further evidence associating hemolytic uremic syndrome with infection by Verotoxin-producing Escherichia coli O157:H7. | Q33453243 | ||
| Hemolytic uremic syndrome and diarrhea associated with Escherichia coli O157:H7 in a day care center | Q33453248 | ||
| The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli | Q33457864 | ||
| Adverse Effect of Lomotil Therapy in Shigellosis | Q34213819 | ||
| Experimental Shigella infections. VI. Role of the small intestine in an experimental infection in guinea pigs | Q40253566 | ||
| Antibiotics for Escherichia coli O157: H7 enteritis? | Q43947533 | ||
| Escherichia coli O157:H7 diarrhea in a nursing home: clinical, epidemiological, and pathological findings | Q44672767 | ||
| Comparison of loperamide with bismuth subsalicylate for the treatment of acute travelers' diarrhea | Q70006016 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Escherichia coli | Q25419 |
| hemolytic-uremic syndrome | Q162266 | ||
| P304 | page(s) | 589-592 | |
| P577 | publication date | 1990-04-01 | |
| P1433 | published in | The Journal of Pediatrics | Q7743611 |
| P1476 | title | Risk factors for the progression of Escherichia coli O157:H7 enteritis to hemolytic-uremic syndrome | |
| P478 | volume | 116 |
| Q27622010 | A mutant Shiga-like toxin IIe bound to its receptor Gb(3): structure of a group II Shiga-like toxin with altered binding specificity |
| Q33497729 | A standard immunoglobulin preparation produced from bovine colostra shows antibody reactivity and neutralization activity against Shiga-like toxins and EHEC-hemolysin of Escherichia coli O157:H7. |
| Q26827657 | Antibiotic treatment of verocytotoxin-producing Escherichia coli (VTEC) infection: a systematic review and a proposal |
| Q42126833 | Antidiarrheal Agents: More to the Apple Sauce Than You Might Think: Treating infectious diarrheas. |
| Q37427662 | Bacterial colitis |
| Q57702450 | Chapter 14 Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura |
| Q43719658 | Chemical synthesis of a P(k)-antigenic globotriose analogue with a functionalized aglycon |
| Q33346852 | Current concepts in the diagnosis and management of thrombotic thrombocytopenic purpura |
| Q33364452 | Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin I. |
| Q33330389 | Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak |
| Q33501155 | Epidemic hemolytic-uremic syndrome in children |
| Q38847100 | Epidemiological and Microbiological Investigation of an Outbreak of Severe Disease from Shiga Toxin-Producing Escherichia coli O157 Infection Associated with Consumption of a Slaw Garnish |
| Q26801344 | Escherichia coli O157 Outbreaks in the United States, 2003-2012 |
| Q35816742 | Escherichia coli O157:H7, other verotoxin-producing E coli and the hemolytic uremic syndrome in childhood |
| Q34391524 | Escherichia coli O157:H7. |
| Q74591007 | Escherichia coli O157:H7: assessing and minimizing the risk from farm to fork |
| Q42721409 | Escherichia coli infections and hemolytic-uremic syndrome |
| Q33488736 | Escherichia coliO157:H7 and the Hemolytic–Uremic Syndrome |
| Q33383008 | Experiences with HUS in Canada: what have we learned about childhood HUS in Canada? |
| Q42964192 | Gender and the progression of Escherichia coli O157:H7 enteritis to haemolytic uraemic syndrome |
| Q42599592 | Genomic analysis of bacteriophage PBECO4 infecting Escherichia coli O157:H7. |
| Q33389799 | Haemolytic anaemia after childhood Escherichia coli O 157 .H7 infection: are females at increased risk? |
| Q57701679 | Hemolytic uremic syndrome |
| Q33361312 | Hemolytic uremic syndrome incidence in New York |
| Q33370290 | Hemolytic uremic syndrome risk and Escherichia coli O157:H7. |
| Q33386652 | Hemolytic-uremic syndrome in Switzerland: a nationwide surveillance 1997-2003. |
| Q33398753 | Hemolytic-uremic syndrome in children. A serious hazard of undercooked beef |
| Q43212890 | High incidence of haemorrhagic colitis due to Escherichia coli O157 in one Scottish town: clinical and epidemiological features |
| Q33494397 | Hypoproteinemia in the hemolytic-uremic syndrome of childhood |
| Q45096420 | In vitro bactericidal activity of antimicrobial agents against enterohaemorrhagic Escherichia coli |
| Q33380239 | Intestinal obstruction during shigellosis: Incidence, clinical features, risk factors, and outcome |
| Q33500281 | L-arginine as a therapeutic approach for the verotoxigenic Escherichia coli-induced hemolytic uremic syndrome and thrombotic thrombocytopenic purpura |
| Q37843732 | Lactoferrin: an iron-binding antimicrobial protein against Escherichia coli infection. |
| Q48352239 | Management of Shiga toxin producing Escherichia coli-infected children: A multi-national, multi-specialty survey |
| Q33494920 | Neurological manifestations of hemorrhagic colitis in the outbreak of Escherichia coli O157:H7 infection in Japan |
| Q24550740 | Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections |
| Q33339140 | Post-diarrhea hemolytic-uremic syndrome: clinical aspects |
| Q44712430 | Postdiarrheal hemolytic uremic syndrome in persons aged 65 and older in foodnet sites, 2000-2006. |
| Q34720491 | Prevalence of Escherichia coli O157 in Saskatchewan cattle: characterization of isolates by using random amplified polymorphic DNA PCR, antibiotic resistance profiles, and pathogenicity determinants |
| Q38360747 | Purification of Shiga-like toxin 1 by pigeon egg white glycoproteins immobilized on Sepharose gels |
| Q33369842 | Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis |
| Q93936211 | Response |
| Q33346480 | Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome |
| Q35616704 | Severe acute diarrhea |
| Q37659792 | Shiga toxins--from cell biology to biomedical applications |
| Q27621547 | Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands |
| Q33876179 | Shigella and Shiga toxin-producing Escherichia coli causing bloody diarrhea in Latin America |
| Q33372310 | Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection? |
| Q38160938 | The Canadian contribution to the science of verotoxigenic Escherichia coli and associated illnesses: the early years |
| Q33338745 | The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients |
| Q71041946 | The hemolytic uremic syndrome |
| Q24623245 | The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections |
| Q34391558 | The role of antibiotics in the treatment of infectious diarrhea |
| Q33374370 | Thrombotic microangiopathies: an update |
| Q43162615 | Verocytotoxin producing Escherichia coli |
Search more.